BACKGROUND: The prediction of which patients with Barrett's metaplasia will develop cancer is difficult. Better genetic characterization of the condition may aid clinicians in devising more effective management and follow-up strategies. METHODS: A review was undertaken of the accumulated genetic data relating to the progression of squamous epithelium to adenocarcinoma. The normal functions of a number of cancer-related genes are described and an explanation is given of how alterations in these genes interfere with normal cell processes and lead to cancer. RESULTS AND CONCLUSION: The main genetic alterations accompanying the progression through dysplasia to adenocarcinoma were collated from 135 papers. The principal genetic changes implicated are the loss of p16 gene expression (by deletion or hypermethylation), the loss of p53 expression (by mutation and deletion), the increase in cyclin D1 expression, the induction of aneuploidy and the losses of the Rb, DCC and APC chromosomal loci.
BACKGROUND: The prediction of which patients with Barrett's metaplasia will develop cancer is difficult. Better genetic characterization of the condition may aid clinicians in devising more effective management and follow-up strategies. METHODS: A review was undertaken of the accumulated genetic data relating to the progression of squamous epithelium to adenocarcinoma. The normal functions of a number of cancer-related genes are described and an explanation is given of how alterations in these genes interfere with normal cell processes and lead to cancer. RESULTS AND CONCLUSION: The main genetic alterations accompanying the progression through dysplasia to adenocarcinoma were collated from 135 papers. The principal genetic changes implicated are the loss of p16 gene expression (by deletion or hypermethylation), the loss of p53 expression (by mutation and deletion), the increase in cyclin D1 expression, the induction of aneuploidy and the losses of the Rb, DCC and APC chromosomal loci.
Authors: S H Doak; G J S Jenkins; E M Parry; F R D'Souza; A P Griffiths; N Toffazal; V Shah; J N Baxter; J M Parry Journal: Gut Date: 2003-05 Impact factor: 23.059
Authors: Lisa A Lai; Rumen Kostadinov; Michael T Barrett; Daniel A Peiffer; Dimitry Pokholok; Robert Odze; Carissa A Sanchez; Carlo C Maley; Brian J Reid; Kevin L Gunderson; Peter S Rabinovitch Journal: Mol Cancer Res Date: 2010-07-20 Impact factor: 5.852
Authors: G J S Jenkins; J Mikhail; A Alhamdani; T H Brown; S Caplin; J M Manson; R Bowden; N Toffazal; A P Griffiths; J M Parry; J N Baxter Journal: J Clin Pathol Date: 2007-01-12 Impact factor: 3.411
Authors: Charles A Fox; Lisa M Sapinoso; Hong Zhang; Wanghai Zhang; Howard L McLeod; Gina R Petroni; Tarun Mullick; Christopher A Moskaluk; Henry F Frierson; Garret M Hampton; Steven M Powell Journal: Neoplasia Date: 2005-04 Impact factor: 5.715
Authors: Franziska Pühringer-Oppermann; Michael Stahl; Gisela Keller; Mario Sarbia Journal: J Cancer Res Clin Oncol Date: 2006-03-15 Impact factor: 4.553
Authors: Marinke Westerterp; Henderik L van Westreenen; Marije Deutekom; Jaap Stoker; Paul Fockens; Emile Fi Comans; John Tm Plukker; Patrick Mm Bossuyt; J Jan B van Lanschot; Gerrit W Sloof Journal: Patient Prefer Adherence Date: 2008-02-02 Impact factor: 2.711